UPDATE 1-ZymoGenetics cuts jobs, stops immunology research

* Says cutting workforce by about 15 pct

* Sees charge of $3.5 mln in Q4

* To discontinue all ongoing immunology research

Dec 3 (Reuters) - Biotechnology firm ZymoGenetics Inc ZGEN.O said it will cut its workforce by about 15 percent and discontinue all its ongoing immunology discovery research programs to focus its efforts on building the market for its synthetic blood-clotting enzyme Recothrom.

The company, which expects to take related charges of about $3.5 million in the fourth quarter, said it will reduce its workforce by 52 employees, in addition to the 161 employees terminated in April.

In November, ZymoGenetics was sued by King Pharmaceuticals Inc KG.N for engaging in unfair competition, false advertising and trademark infringement related to Recothrom and ZymoGenetics was temporarily restrained from marketing the drug.

As of Sept. 30, the company had $103.4 million in cash and cash equivalents.

Shares of the company closed down 1.5 percent at $6.60 Thursday on Nasdaq. (Reporting by Krishnakali Sengupta in Bangalore; Editing by Anil D'Silva)

((krishnakali.sengupta@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: krishnakali.sengupta.reuters.com@reuters.net))